secwatch.observer — SEC 8-K summary
======================================

Issuer:     Chemomab Therapeutics Ltd. (CMMB)
CIK:        0001534248
Form:       8-K/A
Filed at:   2021-11-12T23:59:59+00:00
Accession:  0001178913-21-003512
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Chemomab appoints Donald Marvin as CFO & COO, replacing Sigal Fattal effective Nov 8, 2021
--------------------------------------------------------------------------------

- Sigal Fattal's engagement as interim CFO concluded by mutual agreement; she remains as senior consultant.
- Donald Marvin named CFO, EVP & COO; base salary $460K, annual bonus target 45% of base.
- Marvin receives 1.5% equity (4-yr vest) + up to 0.5% for strategic goals, $25K signing bonus.
- Severance package of 12 months, increasing by 1 month every 2 years (max 18 months).
- Marvin brings 35+ years experience; no family relationships or reportable transactions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534248/000117891321003512/0001178913-21-003512-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534248/000117891321003512/form8k.htm
  HTML page:      https://secwatch.observer/filing/0001178913-21-003512

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer